- Home
- DSM vs FDMT Comparison
DSM vs FDMT Comparison
Compare DSM & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSM
- FDMT
- Stock Information
- Founded
- DSM 1989
- FDMT 2013
- Country
- DSM United States
- FDMT United States
- Employees
- DSM N/A
- FDMT N/A
- Industry
- DSM Investment Managers
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- DSM Finance
- FDMT Health Care
- Exchange
- DSM Nasdaq
- FDMT Nasdaq
- Market Cap
- DSM 280.8M
- FDMT 192.2M
- IPO Year
- DSM N/A
- FDMT 2020
- Fundamental
- Price
- DSM $5.60
- FDMT $4.32
- Analyst Decision
- DSM
- FDMT Buy
- Analyst Count
- DSM 0
- FDMT 10
- Target Price
- DSM N/A
- FDMT $32.33
- AVG Volume (30 Days)
- DSM 161.7K
- FDMT 436.5K
- Earning Date
- DSM 01-01-0001
- FDMT 08-07-2025
- Dividend Yield
- DSM 3.97%
- FDMT N/A
- EPS Growth
- DSM N/A
- FDMT N/A
- EPS
- DSM N/A
- FDMT N/A
- Revenue
- DSM N/A
- FDMT $23,000.00
- Revenue This Year
- DSM N/A
- FDMT $13,048.65
- Revenue Next Year
- DSM N/A
- FDMT N/A
- P/E Ratio
- DSM N/A
- FDMT N/A
- Revenue Growth
- DSM N/A
- FDMT N/A
- 52 Week Low
- DSM $4.69
- FDMT $2.24
- 52 Week High
- DSM $6.05
- FDMT $28.93
- Technical
- Relative Strength Index (RSI)
- DSM 46.90
- FDMT 57.43
- Support Level
- DSM $5.55
- FDMT $3.86
- Resistance Level
- DSM $5.67
- FDMT $4.48
- Average True Range (ATR)
- DSM 0.04
- FDMT 0.28
- MACD
- DSM 0.00
- FDMT 0.01
- Stochastic Oscillator
- DSM 30.00
- FDMT 89.81
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.